DOCSLIB.ORG

Antitubercular Drugs Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antitubercular Drugs Pdf Antitubercular drugs pdf Continue Tb treatment is aimed at shortening the clinical course of tuberculosis, preventing complications, preventing the development of delay and/or subsequent recurrences, and reducing the likelihood of transmission of tuberculosis. In patients with laten tuberculosis, the purpose of therapy is to prevent the progression of the disease. View full drug information This is the primary drug selected for use in preventive therapy and for use in active tuberculosis combination therapy. It is also used in combination with Rifapentin for adults and children aged 2 years or older with laten TB as a once-weekly DOT therapy for 12 weeks. Its mechanism of action is not fully understood, but isosiosied can inhibit the synthesis of myclic acid, resulting in disruption of the bacterial cell wall. In patients receiving active TB, 25-50 mg of pyridoxin should be taken orally once a day to prevent peripheral neuropathy. See the full drug information Rifampin is used in co-ed with at least 1 other anti-tuberculosis drug active in TB. Inhibits DNA-dependent RNA polymerase activity in bacterial cells, but not mammalian cells. Cross resistance may occur. In most susceptible cases, the patient undergoes 6 months of treatment. Treatment lasts for 9 months if the patient's sputum herniation results are positive after 2 months of treatment. View full drug information This is an analogue of nicotinamide pirazine, which is bacteriostatic or bactericidal against M tuberculosis, depending on the concentration of the drug reached at the site of infection. The mechanism of action of pyrazinamide is unknown. Inject the drug into the initial 2 months of a 6-month or longer treatment regimen with drug-sensitive TB. Treat drug-resistant TB with personalized treatments. View the complete drug information on Ethambutol diffuse actively growing mycobacterial cells (eg, tuberculosis bacillus). This impairs cell metabolism by inhibiting the synthesis of 1 or more metabolites, which in turn causes cell death. There's no evidence of cross-resistance. Mycobacterial resistance is common with previous therapy. In such cases, use ethambutol in combination with second-line drugs that have not previously been insansed. Administered every 24 hours until prolonged bacteriological transformation and maximum clinical improvement are observed. Absorption is not significantly changed by food. Adverse effects of ethambutol include optical neuritis, which is usually reversible by discontinuing the drug. During the period when the patient receives a dose of 25 mg/kg per day, a monthly eye test is recommended. View complete drug information on Streptomycin sulfate, aminoglycolyside, used to treat susceptible mycobacterial infections. Use this substance in combination with other antituberculous drugs isoniazide, ethambutol, rifampin). Although the total duration of treatment for tuberculosis is at least 6 months, streptomycin streptomycin it is not commonly used throughout the course of treatment because of toxicity concerns. The drug is recommended if less potentially dangerous therapeutic drugs are ineffective or contraindicated. View the full drug information on Levofloxacin, a second-line antituberculous drug, used in co-rifampin and other antituberculous agents to treat most cases of multidrug-resistant TB (MDR-TB). In a good safety profile, long-term use among fluoroquinolones has made levofloxacin the preferred oral agent for the treatment of MDR-TB caused by organisms resistant to first-line drugs. Levofloxacin triggers the effects of inhibition through bacterial topoimic topoimyrases IV and DNA gyrases, which are necessary for DNA replication, transcription, repair, and recombination. View the full drug information on Moxifloxacin, a second-line antituberculous drug, inhibiting the subunits of DNA gyrases, leading to inhibition of bacterial DNA replication and transcription. Moxifloxacin can be used on MDR-TB by organisms known or suspected to be sensitive to fluoroquinolones, or if the first-line medicinal product cannot be used due to intolerance. View full drug information This substance is used twice a week as part of a multi-drug treatment for 2 months during the intensive phase of TB treatment, and then once a week for 4 months, together with ioniazid or the corresponding active ingredient in susceptible organisms. The medicine is indicated as treatment once a week for adults and children aged 2 years or older with laten TB combined with iszolaziazide. Rifapentin inhibits DNA-dependent RNA polymerase in susceptible strains of M tuberculosis organisms. It should not be used to treat active tuberculosis after 2 months of treatment with HIV infection or positive tb cultures. See the full drug information, etionamide is a second-line drug that is bacteriostatic or bactericidal against M tuberculosis, depending on the concentration of the drug reached at the site of infection. It is recommended if treatment with first-line drugs (isoniazid, rifampin) is unsuccessful. Etionamide can be used to treat any form of active tuberculosis. However, it should only be used with other effective tuberculosis drugs. See the full drug information amikacin is a second-line drug used to treat patients with MDR-TB or those who do not tolerate first-line therapies. This agent irreversibly binds to the 30S subunit of bacterial ribosomes, blocking the detection step of protein synthesis and causing growth inhibition. View the complete drug information on Cycloserine, a second-line TB drug, inhibiting cell wall synthesis of susceptible strains of gram-positive and gram-negative bacteria and M tuberculosis. This Structural analogue d-alanine, which antagonizes the role of D-alanine in bacterial cell wall synthesis, inhibits growth. Like all antituberculosis drugs, cicloserin is With other effective TB drugs and not the only therapeutic agent, look at the complete drug information Capreomycin, which is taken from Streptomyces capreolus, is a second-line drug used in co-ed with other antituberculous agents in lung infections caused by creomin-sensitive strains of M tuberculosis. Creomicin is used only if first-line agents (e.g. isoliazida, rifampin) have been ineffective or cannot be used due to toxicity or the presence of resistant tuberculosis bacilluses. See full drug information This is an ansamycin antibiotic derived from rifamycin S. Rifabutin inhibits DNA-dependent RNA polymerase, preventing chain initiation. It is used in TB to treat individuals with specific HIV drugs when rifampin is contraindicated (most protease inhibitors). View the complete drug information clofazimine inhibits mycobacterial growth, binding preferably to mycobacterial DNA. It has antimicrobial properties, but its mechanism of action is unknown. It is rarely used to treat MDR-TB. As with any drug for TB, clofazimine is always used in other antituberculous agents. Clofazimine is only available on a patient basis, doctors who submit a test for a new drug (IND) application to the U.S. Food and Drug Administration (FDA). View full drug information This is a bacteriostatic agent that is useful as a second line agent against M tuberculosis. This is the most commonly used MDR-TB, or if treatment with ioniazid or rifampin is not possible. It inhibits the development of bacterial resistance against streptomycin and isolesisida. This substance should be administered with other anti-tuberculosis drugs. View the full drug information on Bedaquiline as a diarylquinoline that inhibits mycobacterial adenosine 5'-triphosphate (ATP) synthase, an enzyme essential for the generation of energy in Mycobacterium tuberculosis. 24 weeks of multidrug therapy (at least 4 other antitubercular medicines) in adults and adolescents aged 5 years and older with pulmonary MDR-TB. Therapy with bedaquiline is reserved if no effective treatment regimen can be provided by other means. It is not recommended for the treatment of latening, extrapulmonary or drug-sensitive tuberculosis. View the full drug information on Nitroimidazooxazine, which kills actively reproducing M tuberculosis by inhibiting myoic acid biosynthesis, thereby blocking cell wall production. As part of combination treatment with bedaquiline and linezolide, it is indicated for the treatment of pulmonary, widely drug-resistant TB (XDR-TB) or treatment-intolerant or unresponsive MDR-TB in adults. Delamanid is a dihydro-nitroimidazooxazole derivative. It works by inhibiting the synthesis of the mycobacterial cell wall. The WHO's treatment of drug-resistant tuberculosis 2019 as an imitator, requires that delamanid be included in the treatment of MDR/rifampin-resistant patients older >3 years of age during longer treatment. Treatment of tuberculosisDifferent pharmaceutical tuberculosis treatments and their measuresSpecialInfected diseases[edit wikidata] Treatment of tuberculosis refers to the medical treatment of infectious disease tuberculosis (TB). The standard short course of treatment for TB is isosiazide (along with pyridoxatic phosphate, peripheral neuropathy caused by isoisiazide, rifampicin (also known as rifampin in the United States), pyrazinamide and ethambutol for two months, followed by isoiazide and rifampicin alone for another four months. The patient is considered free of live bacteria after six months. In laten tuberculosis, the standard treatment alone is a combination of 6-9 months of daily ioniazid or three months per week (12 doses in total) of isiazida/rifapentin. [1] [2] [3] If the body is known to be completely sensitive, treatment
Load more

Recommended publications
  • Clofazimine As a Treatment for Multidrug-Resistant Tuberculosis: a Review
    Scientia Pharmaceutica Review Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review Rhea Veda Nugraha 1 , Vycke Yunivita 2 , Prayudi Santoso 3, Rob E. Aarnoutse 4 and Rovina Ruslami 2,* 1 Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 2 Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia; [email protected] 3 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran—Hasan Sadikin Hospital, Bandung 40161, Indonesia; [email protected] 4 Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, 6255HB Nijmegen, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by Mycobac- terium tuberculosis which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combination of several drugs, and the adverse effects of these drugs are the factors that play a role in the poor outcomes of MDR-TB patients. There have been many studies with repurposed drugs to improve MDR-TB outcomes, including clofazimine. Clofazimine recently moved from group 5 to group B of drugs that are used to treat MDR-TB. This drug belongs to the riminophenazine class, which has lipophilic characteristics and was previously discovered to treat TB and approved for leprosy. This review discusses the role of clofazimine as a treatment component in patients with MDR-TB, and Citation: Nugraha, R.V.; Yunivita, V.; the drug’s properties.
    [Show full text]
  • Inhaled Anti-Tubercular Therapy: Dry Powder Formulations, Device And
    UNI SYDNEY LOGO INHALED ANTI-TUBERCULAR THERAPY: DRY POWDER FORMULATIONS, DEVICE AND TOXICITY CHALLENGES Thaigarajan Parumasivam A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy Faculty of Pharmacy The University of Sydney 2017 STATEMENT OF AUTHENTICITY This thesis is submitted to the University of Sydney in fulfilment of the requirements for the Degree of Doctor of Philosophy. The work described was carried out in the Faculty of Pharmacy and Centenary Institute under the supervision of Professor Hak-Kim Chan and Professor Warwick Britton The work presented in this thesis, is to the best of my knowledge and belief, original except as acknowledged in the text. The contributions of all co-authors in publications included in the body of the thesis have been declared, signed by each co-author and attached as an appendix. I hereby declare that I have not previously or concurrently submitted this material, either in full or in part, for a degree at this or any other institution. Thaigarajan Parumasivam Oct 2016 ii CONTENTS Acknowledgement ................................................................................................................. viii Glossary .................................................................................................................................... x Thesis abstract .......................................................................................................................... 1 Chapter 1 .......................................................................................................................
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Pretomanid Reference Number: CP.PMN.222 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Pretomanid Reference Number: CP.PMN.222 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Pretomanid is a nitroimidazooxazine antimycobacterial drug. FDA Approved Indication(s) Pretomanid is indicated as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitation(s) of use: • Pretomanid tablets are not indicated for patients with: o Drug-sensitive (DS) tuberculosis o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy • Safety and effectiveness of pretomanid tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that pretomanid is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Multi-Drug Resistant Tuberculosis (must meet all): 1. Diagnosis of pulmonary MDR-TB or XDR-TB; 2. Prescribed by or in consultation with an expert in the treatment of tuberculosis; 3.
    [Show full text]
  • Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
    applied sciences Review Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations Rob C. van Wijk 1 , Rami Ayoun Alsoud 1, Hans Lennernäs 2 and Ulrika S. H. Simonsson 1,* 1 Department of Pharmaceutical Biosciences, Uppsala University, Uppsala 75123, Sweden; [email protected] (R.C.v.W.); [email protected] (R.A.A.) 2 Department of Pharmacy, Uppsala University, Uppsala 75123, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-184-714-000 Received: 29 February 2020; Accepted: 25 March 2020; Published: 31 March 2020 Featured Application: Model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations for the treatment of tuberculosis. Abstract: The increasing emergence of drug-resistant tuberculosis requires new effective and safe drug regimens. However, drug discovery and development are challenging, lengthy and costly. The framework of model-informed drug discovery and development (MID3) is proposed to be applied throughout the preclinical to clinical phases to provide an informative prediction of drug exposure and efficacy in humans in order to select novel anti-tuberculosis drug combinations. The MID3 includes pharmacokinetic-pharmacodynamic and quantitative systems pharmacology models, machine learning and artificial intelligence, which integrates all the available knowledge related to disease and the compounds. A translational in vitro-in vivo link throughout modeling and simulation is crucial to optimize the selection of regimens with the highest probability of receiving approval from regulatory authorities.
    [Show full text]
  • Treatment Outcomes of Adjunctive Surgery in Multidrug-Resistant And
    MOJ Surgery Opinion Open Access Treatment outcomes of adjunctive surgery in multidrug-resistant and extensively drug-resistant tuberculosis Opinion Volume 5 Issue 2 - 2017 In 2013, the World Health Organization (WHO) reported that 3.5% and 20.5% of new and previously treated tuberculosis (TB) Attapon Cheepsattayakorn,1,2 Ruangrong cases were multidrug-resistant tuberculosis (MDR-TB, resistant 3 to both isoniazid and rifampicin), respectively, and 9.0% of them Cheepsattayakorn 1 developed extensively drug-resistant tuberculosis (XDR-TB, resistant 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand to isoniazid, rifampicin, a fluoroquinolone, and 1 or greater injectable 2Department of Disease Control, Ministry of Public Health, agent). The WHO has estimated a global prevalence of 660,000 cases Thailand of MDR-TB and 150,000 MDR-TB related deaths annually. A previous 3Department of Pathology, Faculty of Medicine, Chiang Mai multi-country study revealed that among 1,278 MDR-TB cases, University, Thailand around 7% had XDR-TB. Only 136,000 MDR-TB cases (45.3%) Correspondence: Attapon Cheepsattayakorn, 10th Zonal among estimated 300,000 MDR-TB cases have been diagnosed and Tuberculosis and Chest Disease Center, 143 Sridornchai Road 97,000 cases (32.3%) are treated using appropriate regimens based on Changklan Muang Chiang Mai 50100 Thailand , Tel 66-531-407- drug susceptibility testing (DST). In 2013, the treatment success rate 67, 66 5-327-636-4, Fax 665-314-077-3, 665-327-359-0, of MDR-TB is only 48.0%; around 47,000 cases improved clinically Email [email protected]; [email protected] and biologically.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Appraisal of NICE's Cost-Effectiveness Thresholds for Assessing Orphan
    Master's Degree Dissertation Appraisal of NICE’s cost-effectiveness thresholds for assessing orphan drugs Author: Ruodan Nan Master's Degree in Health Economics and Pharmacoeconomics UPF Barcelona School of Management Academic Year 2018 – 2021 Mentor: Laura Vallejo 1 Project performed within the framework of the Health Economics and Pharmacoeconomics program taught by Barcelona School of Management, a centre associated with Pompeu Fabra University 2 Abstract A rare disease is one that affects less than 1 in 2,000 in general population, and they are often chronic and life-threatening [1]. Due to the high cost to develop and small market for orphan drugs, historically manufacturers are reluctantly to explore the rare disease therapeutic areas. There is highly unmet need from patients with rare diseases. As the pharmaceutical expenditure rises, governments around the world are increasingly under pressure to contain the costs on drug reimbursement. Meanwhile patients with rare diseases need to be ensured for access to orphan drugs, and the industry needs to be incentivized to innovate. Health technology assessment and reimbursement bodies set out measures and policies for orphan drugs to be given market access. In this literature review, the landscape of health technology appraisals for orphan drugs in England UK is studied. The process for an orphan drug to gain marketing authorisation in the European Union (EU), the methods and criteria that used by National Institute for Health and Care Excellence (NICE) are reviewed. All orphan drugs with marketing authorisations from European Medicine Agency (EMA) are searched from the agency’s online database, whereas each of the authorised orphan drug is searched in NICE’s database for any technology appraisals and recommendations made for the orphan drug.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • ANTIBIOTIC INHIBITION of CATALYTIC RNA FUNCTION by Jeff
    ANTIBIOTIC INHIBITION OF CATALYTIC RNA FUNCTION by Jeff Rogers B.Sc. (Honours), University of Regina, 1991 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY) We accept this thesis as conforming to the required standard THE UNIVERSITY OF BRITISH COLUMBIA August 1996 ©Jeff Rogers, 1996 In presenting this thesis in partial fulfilment of the requirements for an advanced degree at the University of British Columbia, I agree that the Library shall make it freely available for reference and study. I further agree that permission for extensive copying of this thesis for scholarly purposes may be granted by the head of my department or by his or her representatives. It is understood that copying or publication of this thesis for financial gain shall not be allowed without my written permission. Department The University of British Columbia Vancouver, Canada DE-6 (2/88) ii ABSTRACT A number of compounds inhibit group I intron splicing. Competitive inhibitors include deoxyguanosine, dideoxyguanosine, arginine and streptomycin; the non-competitive inhibitors include members of the aminoglycoside family of antibiotics. Further screening of a collection of antibiotics for their ability to inhibit group I intron splicing identified several novel compounds. In particular, the pseudodisaccharide antibiotic lysinomicin, the peptide antibiotics netropsin and distamycin, and the tetracycline analog chelocardin, were found to inhibit group I intron splicing at concentrations of 250 pM or lower. Inhibition of group I intron splicing by pseudodisaccharide antibiotics was studied in detail. Lysinomicin and three closely related compounds were found to inhibit the self splicing reaction of the Tetrahymena, Bacillus phage SP01 and T4 phage td and sun 7 group I introns at concentrations less than 50 u.M.
    [Show full text]
  • Molecular Mechanism of Viomycin Inhibition of Peptide Elongation in Bacteria
    Molecular mechanism of viomycin inhibition of peptide elongation in bacteria Mikael Holma, Anneli Borga, Måns Ehrenberga, and Suparna Sanyala,1 aDepartment of Cell and Molecular biology, Uppsala University, 75124 Uppsala, Sweden Edited by Joseph D. Puglisi, Stanford University School of Medicine, Stanford, CA, and approved December 16, 2015 (received for review September 2, 2015) Viomycin is a tuberactinomycin antibiotic essential for treating multi- activity of viomycin in genetic code translation (6) and its stabilization drug-resistant tuberculosis. It inhibits bacterial protein synthesis by of peptidyl tRNA in the A site (24). blocking elongation factor G (EF-G) catalyzed translocation of messen- In this study we used rapid kinetics methods in a state-of-the-art ger RNA on the ribosome. Here we have clarified the molecular aspects in vitro translation system with in vivo-like rates (25, 26) to charac- of viomycin inhibition of the elongating ribosome using pre-steady- terize the mechanism of viomycin inhibition of the peptide elongation state kinetics. We found that the probability of ribosome inhibition by cycle. We constructed a quantitative model for viomycin action with viomycin depends on competition between viomycin and EF-G for precise estimates of the model parameters. This model quantifies the binding to the pretranslocation ribosome, and that stable viomycin functional aspects of viomycin inhibition of translocation. It paves the binding requires an A-site bound tRNA. Once bound, viomycin stalls the way for deeper understanding of the basis of the antimicrobial activity ribosome in a pretranslocation state for a minimum of ∼45 s. This of viomycin and the evolution of viomycin resistance, thereby stalling time increases linearly with viomycin concentration.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]